DHANVANTRI JEEVAN REKHA LTD. (ZDHJERK) Fair Value & Analysis
Healthcare · IN · Market cap ₹108M
Strengths
Risks
Fair value as of: Aug 13, 2026
From 24 valuation models · updated 7 days ago
Share price −6.7% over the past month.
A solid business, but screening 36% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹20.74). The favourable scenario is already priced in.
- Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹5.90 – ₹35.85 · fair‑value band ₹12.44 – ₹20.74 · the ₹25.89 price screens above the ₹16.59 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
DHANVANTRI JEEVAN REKHA LTD. (ZDHJERK) currently trades at ₹25.89, while our model-based Fair Value estimate is ₹16.59, implying the stock looks roughly 35.9% overvalued today. The Quality Score stands at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, DHANVANTRI JEEVAN REKHA LTD. generated revenue of ₹259M at a net margin of 1.6%. Revenue grew 24.2% year over year. It earns a return on equity of 3.9%. Net debt stands at ₹8.5M. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹12.44 (bear case) to ₹20.74 (bull case); at ₹25.89, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 28% below its 52-week high and 36% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -31% fair-value upside, at -36%, ZDHJERK screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (₹36.61) versus Economic Profit (₹10.02). Highest evidence: Growth DCF (80).
Notify me when ZDHJERK reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 61 · Market factors (momentum, volatility) 54
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Dhanvantri Jeevan Rekha Limited provides medical and health care services in India. The company operates the multi-specialty Dhanvantri hospital in Meerut.
Full company description
Dhanvantri Jeevan Rekha Limited provides medical and health care services in India. The company operates the multi-specialty Dhanvantri hospital in Meerut. Its Dhanvantri Hospital offers diagnostic and therapeutic services, including cardiology, neurology, respiratory medicine, gastroenterology, gastro surgery, neuro surgery, orthopedic surgery, urology, oral and maxillofaccial surgery, oncology, otorhinolaryngology, pathology, rehabilitation program, and other diagnostic services. The company also operates intensive coronary care units and intensive care units. In addition, it offers services for various breast problems, such as mastalgias, mastopathies, breast lumps, and breast cancer, as well as screening for early breast cancers and training for self-examinations. Dhanvantri Jeevan Rekha Limited was founded in 1993 and is based in Meerut, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
DHANVANTRI JEEVAN REKHA LTD. reported revenue of ₹259M in FY2026 versus ₹168M in FY2022, a compound +11.4%/yr. Reported net income was ₹4.0M in FY2026, compounding −5.0%/yr from FY2022.
ZDHJERK screens 36% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 267 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $414.59 | $547.67 | +32% |
| Fresenius SE FRE | €46.82 | €32.15 | -31% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | -46% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.09 | R$47.31 | +43% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,818 | ₹2,955 | -66% |
| Aier Eye Hospital Group 300015 | ¥8.87 | ¥7.67 | -14% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,008 | ₹284.87 | -72% |
| Bangkok Dusit Medical Services Public Company BDMS | 19.40 THB | 18.57 THB | -4% |
| Fortis Healthcare Limited FORTIS | ₹906.15 | ₹300.29 | -67% |
Compare DHANVANTRI JEEVAN REKHA LTD. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is DHANVANTRI JEEVAN REKHA LTD. (ZDHJERK) overvalued or undervalued?
What is the fair value of ZDHJERK?
What is the quality score of ZDHJERK?
What is the revenue of DHANVANTRI JEEVAN REKHA LTD. (ZDHJERK)?
What is the net profit margin of ZDHJERK?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track DHANVANTRI JEEVAN REKHA LTD. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.